Global Cardiac Surgery and Heart Valve Devices Market Size By Type (Cardiac Surgery Devices, Heart Valve Devices), By Application (Hospitals, Ambulatory Surgical Centres), By Region, And Segment Forec...

The Global Cardiac Surgery and Heart Valve Devices Market was valued at USD 9.3 billion in 2023 and is projected to reach USD 17.6 billion by 2031, growing at a CAGR of 8.2% during the forecast period from 2023 to 2031. The increasing prevalence of cardiovascular diseases, rising geriatric population, and rapid advancements in minimally invasive cardiac surgeries are the primary factors driving market growth. Additionally, the global healthcare sector is witnessing an upsurge in the adoption of technologically advanced heart valve repair and replacement devices, contributing to the market’s expansion.

Drivers:

1. Growing Prevalence of Cardiovascular Diseases:

Heart diseases remain the leading cause of mortality globally. Conditions such as valvular heart disease, coronary artery disease, and arrhythmias are increasing in prevalence, necessitating surgical interventions and valve replacements.

2. Advancements in Minimally Invasive Surgery (MIS):

Technological innovations such as transcatheter aortic valve replacement (TAVR) and robot-assisted cardiac surgeries are significantly reducing patient recovery time, hospitalization duration, and surgical risks, thereby boosting market adoption.

3. Aging Global Population:

The incidence of cardiac disorders is notably higher among the elderly. As the global geriatric population continues to grow, the demand for cardiac surgeries and valve devices is anticipated to surge accordingly.

Restraints:

1. High Procedure and Device Costs:

Cardiac surgeries and heart valve devices involve substantial costs, limiting accessibility for patients in low-income or underinsured regions.

2. Regulatory Hurdles and Product Recalls:

Stringent regulatory frameworks and the possibility of product recalls due to device malfunction or post-market complications pose challenges to manufacturers.

Opportunity:

1. Rise in Emerging Markets:

Countries in Asia-Pacific, Latin America, and the Middle East are rapidly upgrading healthcare infrastructure and increasing investments in cardiac care, offering vast growth opportunities for market players.

2. Expansion of Transcatheter Valve Therapies:

The increasing adoption of TAVR and other catheter-based interventions in treating a broader patient population, including those with low and intermediate surgical risk, is unlocking new revenue streams.

Market by System Type Insights:

By system type, Heart Valve Devices (including mechanical, tissue, and transcatheter heart valves) dominated the market in 2023. The adoption of minimally invasive valve replacement therapies like TAVR is rising rapidly due to reduced surgical complications and improved patient outcomes. Mechanical valves are preferred for their durability, while tissue valves are gaining popularity due to reduced need for long-term anticoagulation therapy.

Market by End-use Insights:

In 2023, Hospitals & Cardiac Centers represented the largest end-use segment, holding over 60% of the market share. The availability of specialized cardiovascular surgeons, advanced surgical suites, and integrated post-operative care services makes hospitals the primary choice for cardiac procedures. Ambulatory surgical centers (ASCs) are expected to grow steadily due to their cost-effectiveness and shorter recovery periods.

Market by Regional Insights:

North America dominated the global cardiac surgery and heart valve devices market in 2023, owing to a high prevalence of heart disease, favorable reimbursement frameworks, and a robust healthcare infrastructure. Asia-Pacific is projected to experience the fastest growth rate during the forecast period, attributed to increasing healthcare investments, a growing aging population, and the rising awareness of cardiovascular health in nations like China, India, and Japan.

Competitive Scenario:

Key players in the global market include Medtronic plc, Edwards Lifesciences Corporation, Abbott Laboratories, LivaNova PLC, Boston Scientific Corporation, CryoLife, Inc., Micro Interventional Devices, Inc., and JenaValve Technology, Inc. These companies are emphasizing R&D investments, product innovation, strategic mergers, and regulatory approvals to strengthen their market positions.

Recent Developments:

In 2024, Edwards Lifesciences received expanded FDA approval for its SAPIEN 3 Ultra TAVR system, allowing use in intermediate-risk patients.

Medtronic launched the Evolut FX, an advanced self-expanding TAVR system, in Europe and North America in late 2023.

Abbott announced successful trials for its novel minimally invasive mitral valve repair device in early 2025, showing promising patient outcomes.

Scope of Work – Global Cardiac Surgery and Heart Valve Devices Market

Report Metric Details

Market Size (2023) USD 9.3 billion

Projected Market Size (2031) USD 17.6 billion

CAGR (2023–2031) 8.2%

Market Segments By System Type (Heart Valve Devices, Equipment), By End-use (Hospitals, Cardiac Centers, ASCs), By Region

Growth Drivers Rising cardiac disease prevalence, aging population, adoption of minimally invasive surgeries

Opportunities Expansion of TAVR, growth in emerging markets

FAQs:

1) What is the current market size of the Global Cardiac Surgery and Heart Valve Devices Market?

The market was valued at USD 9.3 billion in 2023.

2) What is the major growth driver of the Global Cardiac Surgery and Heart Valve Devices Market?

The major driver is the rising prevalence of